Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li(Unknown), Gary D. Steinberg(Rush University Medical Center), Seung Il Jung(Chonnam National University Hwasun Hospital), Shane M. Pearce, Edward Uchio(University of California, Irvine), Daniel M. Geynisman(Fox Chase Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Donald L. Lamm(The University of Texas System), James M. Burke(Scripps Research Institute), Jong Kil Nam(Pusan National University Yangsan Hospital), Seok Ho Kang(Yonsei University), Trinity J. Bivalacqua(University of Pennsylvania), Joseph M Jacob(SUNY Upstate Medical University), Paras Shah(Mayo Clinic in Arizona), Kirk A. Keegan(Vanderbilt University Medical Center), Tyler F. Stewart(University of California San Diego), Rian J. Dickstein(Chesapeake Urology Associates), Joshua J. Meeks(Northwestern University)
Cited by 64
Related Papers
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
Prostate Cancer, Version 1.2016
|Journal of the National Comprehensive Cancer Network|2016|656
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532